Vaping does not have a formal medical approval for treating any disease, but it has a growing role in two areas: helping people quit smoking and delivering certain medications through the lungs. The picture is nuanced. No country has approved e-cigarettes as a prescription medicine for smoking cessation, yet clinical evidence supports their effectiveness, and at least one drug that works on vaporization principles has received FDA approval for a psychiatric condition.
Vaping as a Smoking Cessation Tool
The strongest medical case for vaping is as a way to stop smoking combustible cigarettes. A landmark randomized trial published in the New England Journal of Medicine assigned nearly 900 smokers to either e-cigarettes or traditional nicotine replacement products like patches and gum. After one year, 18% of the e-cigarette group had stayed smoke-free, compared with 9.9% of those using nicotine replacement. That’s roughly double the quit rate.
Despite results like these, no regulatory body has classified e-cigarettes as a medical device or prescription treatment. The UK’s National Health Service, which is generally more supportive of vaping for harm reduction than most health agencies, still does not offer e-cigarettes on prescription. You cannot get one from a GP. The NHS does, however, acknowledge that combining an e-cigarette with support from a local stop-smoking service gives people a strong chance of quitting.
In the United States, the FDA has authorized 39 specific e-cigarette products for legal sale, from brands including JUUL, Vuse, NJOY, and Logic. These authorizations are limited to tobacco and menthol flavors. The FDA is careful to note that authorization does not mean these products are safe or “FDA approved” in the way a medicine would be. It means the agency determined that allowing them on the market could benefit public health, primarily by giving current smokers a less harmful alternative.
How Toxicant Exposure Compares to Cigarettes
The medical interest in vaping hinges on a simple idea: if you can deliver nicotine without burning tobacco, you eliminate most of the chemicals that cause cancer, lung disease, and heart disease. Research published in JAMA Network Open measured biomarkers in the bodies of people who used only e-cigarettes and compared them to exclusive cigarette smokers. The differences were striking.
Levels of a key carcinogen biomarker (linked to one of the most potent cancer-causing compounds in tobacco) were about 98% lower in e-cigarette users than in cigarette smokers. Biomarkers for acrylonitrile, a toxic industrial chemical found in cigarette smoke, were 97% lower. Exposure to acrolein, which damages the lining of the lungs, was 60% lower. Across nearly every category of harmful compound, including cancer-causing hydrocarbons and volatile organic compounds, e-cigarette users showed significantly reduced levels.
That said, exposure was not zero. E-cigarette users still showed measurably higher levels of nicotine, certain metals, and some toxic compounds compared to people who used no tobacco or nicotine products at all. Vaping is substantially less toxic than smoking, but it is not toxin-free.
Vaporization for Delivering Medications
Beyond nicotine, researchers and pharmaceutical companies are exploring vaporization as a drug delivery platform. Inhaling a vaporized medication gets it into the bloodstream faster than swallowing a pill, because the lungs offer a massive surface area with thin membranes that absorb compounds almost instantly. This makes vaporization attractive for situations where speed matters.
The FDA approved a product called ADASUVE in 2012 that uses a technology called Staccato to deliver a vaporized psychiatric medication for managing acute agitation in people with schizophrenia or bipolar I disorder. The patient inhales once, and the drug reaches the brain within minutes. This is the closest thing to a true “medical vape” currently on the market.
Several other vaporized drugs are in development using the same delivery platform. These include treatments for epileptic seizures, Parkinson’s disease symptoms, and cyclic vomiting syndrome. A separate product using a different vaporization approach completed mid-stage clinical trials for treating respiratory distress syndrome in premature infants, delivering a lung surfactant without requiring a breathing tube.
Researchers have also tested vaporizer-based delivery of common bronchodilators used for asthma and chronic obstructive pulmonary disease. The goal is to improve how much of the drug actually reaches the lungs compared to traditional inhalers, which often deposit a large portion of the medication in the mouth and throat.
Medical Cannabis and Vaporization
In states and countries where medical cannabis is legal, vaporizing is one of the most common methods of administration. Vaporizers heat cannabis to a temperature that releases its active compounds without combustion, which avoids producing tar and many of the toxic byproducts of smoking.
Research comparing vaporized and smoked cannabis shows that both deliver similar blood levels of THC and produce comparable peak effects. One study found that infrequent cannabis users actually had higher blood THC levels and stronger subjective effects after vaporizing than after smoking the same dose. Interestingly, the effects of vaporized cannabis wore off faster, typically within 15 minutes to an hour, while the effects of smoked cannabis lingered for 1.5 to 3.5 hours. For medical users who want precise, shorter-duration dosing, this can be an advantage.
Known Health Risks of Vaping
Vaping carries its own set of health concerns. Nicotine in any form raises heart rate and blood pressure, and research has shown that e-cigarette use increases aortic stiffness in young users, a measure of blood vessel health linked to long-term cardiovascular risk.
The most dramatic safety signal came in 2019 and 2020, when a wave of severe lung injuries swept across the United States. The condition, called EVALI (e-cigarette or vaping product use-associated lung injury), caused symptoms including shortness of breath, chest pain, fever, and nausea. Imaging typically showed widespread inflammation across both lungs. The primary culprit turned out to be vitamin E acetate, an oily additive used as a thickener in black-market THC vaping cartridges. A study found vitamin E acetate in the lung fluid of 48 out of 51 patients with EVALI, while it was absent in e-cigarette users without lung disease. The outbreak largely subsided once the additive was identified and illicit products were targeted, but it underscored that what goes into a vaping device matters enormously.
Long-term effects of nicotine vaping over decades remain unknown. The technology has only been widely used since the early 2010s, which means there simply isn’t enough data to know what 20 or 30 years of daily use does to the lungs and cardiovascular system. For someone who has never smoked, the risk-benefit calculation is straightforward: there is no medical reason to start vaping. For someone currently smoking a pack a day, switching completely to a regulated e-cigarette product meaningfully reduces exposure to the compounds most likely to cause cancer and lung disease.